Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of deferoxamine mesylate for injection in treating senile bone loss and bone marrow stem cell aging

A technology of deferoxamine mesylate and bone marrow stem cells, which is applied in the field of medicine, can solve the problems of the decrease in the number and activity of autologous BMSC cells, achieve the effect of low toxicity and ensure safety

Pending Publication Date: 2020-08-18
FIRST HOSPITAL AFFILIATED TO GENERAL HOSPITAL OF PLA
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] The object of the present invention is to provide a kind of application of deferoxamine mesylate for injection in the treatment of age-related bone loss and bone marrow stem cell aging, so as to solve the problem that the cell number and activity of autologous BMSC decrease with aging, By injecting this drug, the vitality of autologous BMSCs in the elderly can be enhanced, and the clinical therapeutic effect of autologous BMSCs can be improved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of deferoxamine mesylate for injection in treating senile bone loss and bone marrow stem cell aging
  • Application of deferoxamine mesylate for injection in treating senile bone loss and bone marrow stem cell aging
  • Application of deferoxamine mesylate for injection in treating senile bone loss and bone marrow stem cell aging

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0036] The technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are a part of the embodiments of the present invention, but not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts shall fall within the protection scope of the present invention.

[0037] 1. The therapeutic effect of deferoxamine mesylate (DFO) for injection on osteoporosis in aged rats was clarified

[0038] Using a 12-month-old rat model, the therapeutic effects of different doses of deferoxamine mesylate for injection (trade name: Desferin) on osteoporosis in aged rats were investigated. Experimental groups: 12-month-old high-dose group (60 mg / kg, n=7), low-dose group (20 mg / kg, n=6), normal saline group (n=6), 2-month-old normal control group (n= 6). The intraperitoneal in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of deferoxamine mesylate for injection in treating senile bone loss and bone marrow stem cell aging. It is shown in the invention that after deferoxamine mesylate is injected into an elderly rat, the phenomenon of bone aging (older bone loss) is reversed, and the aging of bone marrow stromal cells (stem cells) separated from a bone marrow cavity after medicine injection is relieved. It is further proved that intraperitoneal injection of a deferoxamine mesylate medicine can relieve bone mass loss related to rat age and recover aging phenotypes of rat bonemarrow stromal cells, such as promotion of cell growth (cell proliferation and colony formation), increase of osteogenesis, reduction of adipogenesis, reversion of the expression level of cell aging related markers, resistance to oxidative stress and the like.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of deferoxamine mesylate for injection in the treatment of age-related bone loss and bone marrow stem cell senescence. Background technique [0002] Osteoporosis seriously endangers the health of middle-aged and elderly people. my country is the country with the largest number of osteoporosis patients. The functional imbalance of osteoclasts and osteoblasts is the main cause of osteoporosis, which can be traced back to the abnormality of related stem cells that maintain the homeostasis of bone tissue. The aging changes of bone marrow mesenchymal stem cells (BMSCs) are closely related to the occurrence of osteoporosis. [0003] At present, the research status and existing problems at home and abroad are as follows: [0004] Bone is always in a metabolic state of bone remodeling, thereby maintaining a dynamic balance of bone resorption and bone formation. With ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K31/16A61P19/10
CPCA61K9/0019A61K31/16A61P19/10
Inventor 翁土军何莹易玲娴张春丽李利
Owner FIRST HOSPITAL AFFILIATED TO GENERAL HOSPITAL OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com